Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00053300 · ClinicalTrials.gov registry record · Phase 2
Thalidomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00053300 is a Phase 2 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 30 participants.
The verdict
NCT00053300, a Phase 2 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have extensive-stage small cell lung cancer that has responded to previous chemotherapy.
Interventions
- PROCEDURE adjuvant therapy
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2002-08 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00053300
The ClinicalTrials.gov registry entry for NCT00053300 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which adjuvant therapy is the first listed.
NCT00053300 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00053300 about?
NCT00053300 is a clinical study titled "Thalidomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer". RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have extensive-stage small cell lung cancer that has responded to previous chemotherapy.
What is the current status of trial NCT00053300?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2002-08. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00053300?
The interventions under investigation include: adjuvant therapy (PROCEDURE), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00053300?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.